These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 23295832

  • 1. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
    Faggioni M, Hwang HS, van der Werf C, Nederend I, Kannankeril PJ, Wilde AA, Knollmann BC.
    Circ Res; 2013 Feb 15; 112(4):689-97. PubMed ID: 23295832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC.
    Circ Arrhythm Electrophysiol; 2011 Apr 15; 4(2):128-35. PubMed ID: 21270101
    [Abstract] [Full Text] [Related]

  • 4. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B, Walton SD, Ho HT, Belevych AE, Tikunova SB, Bonilla I, Shettigar V, Knollmann BC, Priori SG, Volpe P, Radwański PB, Davis JP, Györke S.
    J Am Heart Assoc; 2018 May 02; 7(10):. PubMed ID: 29720499
    [Abstract] [Full Text] [Related]

  • 5. Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice.
    Ho HT, Thambidorai S, Knollmann BC, Billman GE, Györke S, Kalyanasundaram A.
    Heart Rhythm; 2018 Mar 02; 15(3):430-441. PubMed ID: 29030236
    [Abstract] [Full Text] [Related]

  • 6. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR.
    Circ Res; 2012 Aug 31; 111(6):708-17. PubMed ID: 22828895
    [Abstract] [Full Text] [Related]

  • 7. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R, Wakimoto H, Arad M, Planer D, Konno T, Wang L, Seidman JG, Seidman CE, Berul CI.
    J Cardiovasc Electrophysiol; 2011 Mar 31; 22(3):316-24. PubMed ID: 20807279
    [Abstract] [Full Text] [Related]

  • 8. The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.
    Zhang J, Chen B, Zhong X, Mi T, Guo A, Zhou Q, Tan Z, Wu G, Chen AW, Fill M, Song LS, Chen SR.
    Biochem J; 2014 Jul 01; 461(1):99-106. PubMed ID: 24758151
    [Abstract] [Full Text] [Related]

  • 9. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
    Savio-Galimberti E, Knollmann BC.
    PLoS One; 2015 Jul 01; 10(6):e0131179. PubMed ID: 26121139
    [Abstract] [Full Text] [Related]

  • 10. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Neco P, Torrente AG, Mesirca P, Zorio E, Liu N, Priori SG, Napolitano C, Richard S, Benitah JP, Mangoni ME, Gómez AM.
    Circulation; 2012 Jul 24; 126(4):392-401. PubMed ID: 22711277
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload.
    Hwang HS, Baldo MP, Rodriguez JP, Faggioni M, Knollmann BC.
    Front Physiol; 2019 Jul 24; 10():992. PubMed ID: 31456692
    [Abstract] [Full Text] [Related]

  • 12. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
    Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, Berul CI, Eldar M, Seidman CE, Seidman JG.
    J Clin Invest; 2007 Jul 24; 117(7):1814-23. PubMed ID: 17607358
    [Abstract] [Full Text] [Related]

  • 13. Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    Kannankeril PJ, Shoemaker MB, Gayle KA, Fountain D, Roden DM, Knollmann BC.
    Europace; 2020 Apr 01; 22(4):643-648. PubMed ID: 32091590
    [Abstract] [Full Text] [Related]

  • 14. Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.
    Bai Y, Jones PP, Guo J, Zhong X, Clark RB, Zhou Q, Wang R, Vallmitjana A, Benitez R, Hove-Madsen L, Semeniuk L, Guo A, Song LS, Duff HJ, Chen SR.
    Circ Res; 2013 Aug 16; 113(5):517-26. PubMed ID: 23856523
    [Abstract] [Full Text] [Related]

  • 15. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG.
    J Mol Cell Cardiol; 2011 Jan 16; 50(1):214-22. PubMed ID: 20937285
    [Abstract] [Full Text] [Related]

  • 16. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG.
    Circ Res; 2011 Jul 22; 109(3):291-5. PubMed ID: 21680895
    [Abstract] [Full Text] [Related]

  • 17. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
    Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG.
    Circ Res; 2006 Aug 04; 99(3):292-8. PubMed ID: 16825580
    [Abstract] [Full Text] [Related]

  • 18. Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: Insights from computational modeling.
    Arbel-Ganon L, Behar JA, Gómez AM, Yaniv Y.
    J Mol Cell Cardiol; 2020 Jun 04; 143():85-95. PubMed ID: 32339564
    [Abstract] [Full Text] [Related]

  • 19.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Napolitano C, Mazzanti A, Bloise R, Priori SG.
    ; 1993 Jun 04. PubMed ID: 20301466
    [Abstract] [Full Text] [Related]

  • 20. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B, Bagnall RD, Lam L, Ingles J, Turner C, Haan E, Davis A, Yang PC, Clancy CE, Sy RW, Semsarian C.
    Heart Rhythm; 2016 Aug 04; 13(8):1652-60. PubMed ID: 27157848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.